Eli Lilly and Company
For nearly 150 years, we’ve made significant and game-changing progress on our mission to make life better for people around the world. We’ve remained headquartered in Indianapolis, Indiana, since our founding on May 10, 1876, but our employees now work in countries around the world.
And thanks to the dedication of our diverse global team, we’ve been able to answer the call for new medicines to help solve some of the world’s most significant health challenges
When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
47,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know Team Lilly through our Powered by Purpose series.
NEWS
Please check out the biopharma industry’s COVID-19 stories that are trending for April 20, 2021.
As the U.S. reports surges in COVID-19 infections despite increased enrollment in vaccines, news continues to break about therapies, vaccines, and the risks involved with the new vaccines. Here’s a look.
The reason for the request was the monotherapy antibody therapy is less effective against the COVID-19 variants, such as have risen from the U.K., South Africa and Brazil, as well as the growing B.1.427/B.1.429 California variant.
Under the terms of the deal, SciNeuro is paying Lilly cash upfront as well as various milestone payments and royalties. No financial details were disclosed.
Eli Lilly and Company is set to cut 163 jobs as it closes its Dermira facility in Menlo Park and sells off the latter company’s sweat drug Qbrexza, which is being snatched up by Journey Medical.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
Eli Lilly and Company and Incyte announced today that their Phase III COV-BARRIER study of Olumiant (baricitinib) plus standard of care (SoC) compared to placebo plus SoC failed to hit statistical significance against COVID-19 for its primary endpoint.
The action data was extended by the agency to provide more time to review new data analyses submitted by Lilly, per information requests made by the FDA.
JOBS
IN THE PRESS